← boardnext 2030-06
ZBIO
Zenas BioPharma (USA), LLCdistress 3/10 · well-funded / low risk$31.10-1%today-28% from 52w high
Immunology / Inflammation 3Neurology 1
Lead: Relapsing Multiple Sclerosis · target CD19 · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$719M
Runway
3.4 yrs
Shares 1y
+50%
Price & events
+52.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
+10.1%
1W
+53.9%
1M
+68.2%
3M
+54.8%
6M
+99.1%
1Y
—
2Y
—
5Y
+71.3%
All
Overview
- Market Cap
- $1.96B
- Enterprise Value
- $1.54B
- Volume
- 28.97K
- 52 Week Range
- $11.18 – $43.17
- Total Shares
- 63.13M
- Float Shares
- 41.06M
- Short %
- 28.80%
- % Held by Insiders
- 18.29%
- % Held by Institutions
- 90.52%
- RVOL
- 0.03x
Pipeline stages · 3 programs
Orelabrutinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ObexelimabCD19
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ZB002, Placebo, ZB002, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2030-06 Estimated 50% readout ~2030-08-15 | Phase 3 | Orelabrutinib | Secondary Progressive Multiple Sclerosis | — | recruiting |
| 2030-06 Estimated 50% readout ~2030-08-15 | Phase 3 | Orelabrutinib | Multiple Sclerosis (MS) Primary Progressive | — | recruiting |
| 2026-06-30 | Phase 3 | Obexelimab | Warm Autoimmune Hemolytic Anemia | 134 | active not recruiting |
| 2026-06 | Phase 2 | Obexelimab, Placebo | Systemic Lupus Erythematosus | 190 | recruiting |
| 2025-11-13 | Phase 3 | Obexelimab | IgG4 Related Disease | 194 | active not recruiting |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-08-28 | Phase 2 | Obexelimab, Placebo | Relapsing Multiple Sclerosis | 93 | active not recruiting |
| 2025-07 | Phase 1 | ZB002, Placebo, ZB002, Placebo | Healthy Volunteers, Rheumatoid Arthritis | 72 | recruiting |
Catalyst news & presentations · 12
- 2026Guided 40%trial initiationsecondaryPhase 1ZB021 · Phase 1 clinical development initiation subject to IND clearanceSEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)obexelimab · MAA submission to EMA for obexelimab in IgG4-RDSEC 8-K
- fourth quarter of 2026Guided 70%readoutPhase 2obexelimab · Topline results including biomarker analysis from Phase 2 SunStone trialSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 1ZB022 · Phase 1 clinical development initiation subject to IND clearanceSEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026readoutPhase 2obexelimab · Phase 2 SunStone trial primary endpoint (24-week) dataSEC 8-K
- second quarter of 2026regulatory submissionFiled (NDA/BLA)obexelimab · BLA submission to FDA for obexelimab in IgG4-RDSEC 8-K
- first quarter of 2026readoutPhase 2obexelimab · 24-week data from MoonStone trialSEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 3orelabrutinib · Global Phase 3 trial initiationSEC 8-K
- early in the fourth quarter of 2025readoutPhase 2obexelimab · Phase 2 trial resultsSEC 8-K
- 2025-10-07partnershiporelabrutinib · Exclusive license from InnoCare for orelabrutinib in MS worldwide and non-oncology outside Greater China/SE Asia, plus ZB021 and ZB022 rights.SEC 8-K
- 2025-09-02partnershipobexelimab · Royalty Pharma provides up to $300M in exchange for royalty on obexelimab salesSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $42 (+35% upside) · 8 analysts
- 2026-05-15HC Wainwright & Co.Buy
- 2026-05-14Morgan StanleyEqual-Weight
- 2026-03-17HC Wainwright & Co.Buy
- 2026-03-17GuggenheimBuy
- 2026-03-17CitigroupBuy
- 2026-03-17Morgan StanleyEqual-Weight
Competitors — CD19
Recent news
- 2026-07-20Zenas BioPharma (ZBIO) Gains Nearly 4% as Biotech Momentum Builds - Backspread Trade - dars.gov.et
- 2026-07-17Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees - Quiver Quantitative
- 2026-07-17Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
- 2026-07-17New Zenas hires receive stock awards vesting through 2030 - Stock Titan
- 2026-07-17Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
- 2026-07-16Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz - The National Law Review
- 2026-07-14Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise (NASDAQ:ZBIO) - Seeking Alpha
- 2026-07-10Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.